TY - JOUR
T1 - Development of the participation scale for patients with congestive heart failure
AU - Suzuki, Makoto
AU - Yamada, Sumio
AU - Shimizu, Yuko
AU - Kono, Yuji
AU - Hirashiki, Akihiro
AU - Izawa, Hideo
AU - Murohara, Toyoaki
PY - 2012/6
Y1 - 2012/6
N2 - OBJECTIVE: We report on the development of a participation measure for patients with congestive heart failure (CHF)-the Participation Scale for Patients with CHF (PS-CHF)-and the determination of its unidimensionality, reliability, and validity. DESIGN: This study included two rounds of data collections: 62 patients enrolled in the first round for the purpose of item reduction, and 130 CHF patients and 96 healthy controls participated in the second round for questionnaire validation. RESULTS: The PS-CHF was organized into five items designed to ask about limitations to participation. The PS-CHF score ranges from 5 points (lowest level of participation) to 20 points (highest level of participation). On Rasch analysis, the item calibrations ranged from +0.51 logit for the most difficult item to -0.56 logit for the least difficult item. The range of mean square statistics values was 1.20-0.81 for infit and 1.34-0.72 for outfit. The intraclass correlation coefficient between scores from two successive administrations of the PS-CHF, separated by 2 wks, was 0.94. The total PS-CHF score in CHF patients was significantly lower than in healthy controls. CONCLUSIONS: The PS-CHF was developed to determine a disease-specific participation measure for patients with CHF. The PS-CHF may serve as a clinically meaningful outcome measure for CHF patients.
AB - OBJECTIVE: We report on the development of a participation measure for patients with congestive heart failure (CHF)-the Participation Scale for Patients with CHF (PS-CHF)-and the determination of its unidimensionality, reliability, and validity. DESIGN: This study included two rounds of data collections: 62 patients enrolled in the first round for the purpose of item reduction, and 130 CHF patients and 96 healthy controls participated in the second round for questionnaire validation. RESULTS: The PS-CHF was organized into five items designed to ask about limitations to participation. The PS-CHF score ranges from 5 points (lowest level of participation) to 20 points (highest level of participation). On Rasch analysis, the item calibrations ranged from +0.51 logit for the most difficult item to -0.56 logit for the least difficult item. The range of mean square statistics values was 1.20-0.81 for infit and 1.34-0.72 for outfit. The intraclass correlation coefficient between scores from two successive administrations of the PS-CHF, separated by 2 wks, was 0.94. The total PS-CHF score in CHF patients was significantly lower than in healthy controls. CONCLUSIONS: The PS-CHF was developed to determine a disease-specific participation measure for patients with CHF. The PS-CHF may serve as a clinically meaningful outcome measure for CHF patients.
UR - http://www.scopus.com/inward/record.url?scp=84862779115&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84862779115&partnerID=8YFLogxK
U2 - 10.1097/PHM.0b013e31824ad653
DO - 10.1097/PHM.0b013e31824ad653
M3 - Article
C2 - 22377827
AN - SCOPUS:84862779115
SN - 0894-9115
VL - 91
SP - 501
EP - 510
JO - American Journal of Physical Medicine and Rehabilitation
JF - American Journal of Physical Medicine and Rehabilitation
IS - 6
ER -